Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry

Información del proyecto

Genome Biologics

Identificador del acuerdo de subvención: 773750

DOI

10.3030/773750

Proyecto cerrado

Fecha de la firma de la CE 12 Mayo 2017

Fecha de inicio 1 Junio 2017

Fecha de finalización 30 Septiembre 2017

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

GENOME BIOLOGICS UG
Germany

Periodic Reporting for period 1 - Genome Biologics (Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry)

Período documentado: 2017-06-01 hasta 2017-09-30

Resumen del contexto y de los objetivos generales del proyecto

Modern drug discovery is inefficient, expensive and risky. Due to high development costs, diseases with smaller market share, such as rare diseases are only satisfied in 5% of cases leaving nearly 350mln people worldwide without any treatments. The Genome Biologics GENIMAPS® and GENISYST® patented drug discovery and testing platform overcomes the inefficiencies of pre-clinical studies with its unique combination of genomics, molecular science and. Using our proprietary Artificial Intelligence-driven Drug-Disease matching platform (GENIMAPS®) and our patented single cell transgenic technology (GENISYST®), the platform reduces drug development or drug repurposing time and costs by a factor of 10, allowing pharmaceuticals companies to bring drug candidates into phase 2/3 clinical trials in as little as 3-6 months, instead of 7-10 years with current methodologies.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Out of the seventeen organisations contacted we have identified a strong interest in our technologies in multiple therapeutic areas, including cardiovascular disease (CVD), Central Nervous System disorders (CNS) and oncology (multiple indications and subtypes).
In addition, we have identified potential interest in our technologies for lifestyle diseases, including Non-Alcoholic Fatty Liver disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), obesity and diabetes, which we are currently following up with one of the potential trial partners for a future project application in Phase 2. Investigation of the regulatory environment within Europe has not revealed any issues apart from the requirement to obtain biosafety approval from the appropriate government biosafety authorities. We have provided price indications and quotations to a number of companies and the response has been very good. All companies see the benefit of our technologies outweighing the cost and therefore are not particularly sensitive to the cost factor. These and other analyses are summarised in the Phase 1 final report.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

In combining the power of our GENIMAPS and GENISYST platform, we have identified and developed 2 promising therapeutic agents for heart failure which demonstrated efficacy in restoring heart function and reducing mortality in rodent pre-clinical studies. If successful in downstream clinical trials, these compounds have the potential to alleviate heart disease in humans and increase life quality and expectancy. In parallel, Genome Biologics have discovered a potential for the repurposing of 5 FDA-approved compounds for the treatment of specific sub-types of prostate cancer in humans. Pending further studies, these compounds could contribute to better treatment options for prostate cancer.

Genome Biologics Technology Advantage